Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives $20.88 Consensus Price Target from Analysts

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eight research firms that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $20.88.

A number of analysts have weighed in on TEVA shares. Barclays boosted their price target on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 18th. JPMorgan Chase & Co. boosted their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a report on Monday, October 21st. Finally, StockNews.com downgraded Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a report on Wednesday, December 18th.

Insider Activity

In other news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the sale, the executive vice president now owns 44,104 shares of the company's stock, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Roberto Mignone sold 286,000 shares of the business's stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the sale, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. This represents a 29.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is owned by company insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of institutional investors have recently bought and sold shares of TEVA. FMR LLC raised its stake in shares of Teva Pharmaceutical Industries by 49.5% in the 3rd quarter. FMR LLC now owns 62,740,763 shares of the company's stock valued at $1,130,589,000 after buying an additional 20,762,226 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd raised its position in Teva Pharmaceutical Industries by 6.8% in the third quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company's stock worth $621,337,000 after purchasing an additional 2,204,623 shares in the last quarter. State Street Corp raised its position in Teva Pharmaceutical Industries by 10.0% in the third quarter. State Street Corp now owns 19,500,683 shares of the company's stock worth $351,402,000 after purchasing an additional 1,778,268 shares in the last quarter. Geode Capital Management LLC lifted its stake in Teva Pharmaceutical Industries by 3.4% during the third quarter. Geode Capital Management LLC now owns 8,792,011 shares of the company's stock worth $157,571,000 after purchasing an additional 291,124 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in Teva Pharmaceutical Industries by 13.4% during the second quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company's stock valued at $141,839,000 after purchasing an additional 1,031,400 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Down 1.2 %

TEVA traded down $0.27 on Monday, reaching $21.68. 7,199,934 shares of the company traded hands, compared to its average volume of 9,598,934. Teva Pharmaceutical Industries has a 52-week low of $10.83 and a 52-week high of $22.80. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. The company has a market cap of $24.56 billion, a price-to-earnings ratio of -25.50, a PEG ratio of 1.06 and a beta of 0.73. The stock's 50 day moving average price is $19.14 and its 200-day moving average price is $18.16.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.